The number of diagnosed prevalent cases of JIA in the countries under study will remain relatively stable over the 20 years of our forecast period. Of the countries considered in this analysis…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or…
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Simponi, and UCB’s Cimzia) are approved to treat nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe and are…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AxSpA patient populations covering 171 countries and more than 99%…
TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g.,…
Renal inflammation associated with SLE, also known as LN, is among the most serious manifestations of the disease. Until recently, no therapy was specifically approved for LN. Most treatments are…
Clarivate Epidemiology’s coverage of Sjogren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…